Food and Drug Administration Center for Drug Evaluation and Research Small Business and Industry Assistance Regulatory Education for Industry Generic Drugs Forum; Public Conference, 14734 [2017-05602]
Download as PDF
14734
Federal Register / Vol. 82, No. 54 / Wednesday, March 22, 2017 / Notices
asabaliauskas on DSK3SPTVN1PROD with NOTICES
The Draft EA evaluates the potential
environmental impacts that may result
from the Proposed Action (referred to as
the Build Alternative) and the No Build
Alternative on the natural and built
environment. Potential impacts of each
alternative are evaluated on the
following resource categories:
Socioeconomics; land use; zoning;
public policy; community facilities;
transportation; air quality; noise;
cultural resources; urban design and
visual resources; natural resources;
utilities; waste; and greenhouse gases
and sustainability. The Draft EA
identifies measures to mitigate potential
adverse impacts.
Availability of the Draft EA: Copies of
the Draft EA have been distributed to
Federal, State, and local agencies and
organizations. The Draft EA is available
online in the Federal eRulemaking
Portal at www.regulations.gov,
identified by Docket No. CDC–2017–
0019. Copies of the Draft EA are also
available at:
D Chamblee Public Library, 4115
Clairmont Road, Chamblee GA 30341,
Telephone: (770) 936–1380.
D Doraville Public Library, 3748
Central Ave, Doraville, GA 30340,
Telephone: (770) 936–3852.
D Brookhaven Branch Public Library,
1242 N. Druid Hills Rd NE., Atlanta, GA
30319, Telephone: (404) 848–7140.
D Chamblee City Hall, 5468 Peachtree
Road, Chamblee, GA 30341, Telephone:
(770) 986–5010.
Paper and electronic copies can also
be requested as instructed in the
ADDRESSES section of this document.
Public Meeting: A public meeting will
be held on Wednesday, April 19, 2017
at 2400 Century Center, Century Pkwy.
NE., Atlanta, Georgia 30345. The public
meeting will consist of an Open House
from 6:00 p.m. to 8:00 p.m. EDT. The
meeting will be an open house where
attendees can learn more about the
Master Plan and Draft EA, ask questions,
and submit comments in writing.
Dated: March 15, 2017.
Sandra Cashman,
Executive Secretary, Centers for Disease
Control and Prevention.
[FR Doc. 2017–05624 Filed 3–21–17; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2017–N–0001]
Food and Drug Administration Center
for Drug Evaluation and Research
Small Business and Industry
Assistance Regulatory Education for
Industry Generic Drugs Forum; Public
Conference
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice of public conference.
The Food and Drug
Administration (FDA) Center for Drug
Evaluation and Research (CDER) is
sponsoring a 2-day public conference
entitled ‘‘FDA CDER Small Business
and Industry Assistance (SBIA)
Regulatory Education for Industry
(REdI) Generic Drugs Forum.’’ The goal
of this public conference is to provide
direct, relevant, and helpful information
on the key aspects of the generic drug
development process. Our primary
audience is that of small manufacturers
within the generic drug industry.
However, anyone involved in the
pharmaceutical industry may attend.
DATES: The public conference will be
held April 4–5, 2017, from 8:30 a.m. to
4:30 p.m. See the SUPPLEMENTARY
INFORMATION section for registration
information.
SUMMARY:
The public conference will
be held in the Pinnacle Ballroom
located on the 2nd floor of DoubleTree
by Hilton Hotel, 8727 Colesville Rd.,
Silver Spring, MD 20910.
FOR FURTHER INFORMATION CONTACT:
Brenda Stodart, Center for Drug
Evaluation and Research, Food and
Drug Administration, 10001 New
Hampshire Ave., Silver Spring, MD
20993–0002, 301–796–6707, email:
cdersbia@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
ADDRESSES:
I. Background
FDA is announcing a public
conference entitled ‘‘FDA CDER Small
Business and Industry Assistance
Regulatory Education for Industry
Generic Drugs Forum.’’ This public
conference is intended to increase the
generic drug industry’s awareness of
applicable FDA regulations.
II. Topics for Discussion at the Public
Conference
This 2-day, FDA-led forum offers the
opportunity to interact with FDA
subject matter experts from across CDER
involved in the Generic Drug Review
VerDate Sep<11>2014
18:14 Mar 21, 2017
Jkt 241001
PO 00000
Frm 00062
Fmt 4703
Sfmt 4703
Program. It will provide up-to-date
information on program progress and
current initiatives and present a highlevel regulatory overview of the
complete ANDA review pathway.
III. Participating in the Public
Conference
Registration: There is no fee to attend
the public conference. Space is limited,
and registration will be on a first-come,
first-served basis. To register, please
complete registration online at: https://
www.fda.gov/Drugs/
DevelopmentApprovalProcess/
SmallBusinessAssistance/
ucm540969.htm?utm_
source=FRN&utm_campaign=GDF2017.
Early registration is recommended.
Registrants will receive email
confirmation when they have been
accepted, and reminder emails will be
sent to registrants 2 days before the
conference. If time and space permit,
onsite registration will be available
beginning at 7:30 a.m. on each day of
the public conference.
If you need special accommodations
due to disability, please contact info@
sbiaevents.com at least 7 days in
advance.
Streaming Webcast of the Public
Conference: This public conference will
also be webcast. Persons interested in
viewing the webcast must register to
receive a confirmation email with the
webcast link.
If you have never attended a Connect
Pro event before, test your connection at
https://collaboration.fda.gov/common/
help/en/support/meeting_test.htm. To
get a quick overview of the Connect Pro
program, visit https://www.adobe.com/
go/connectpro_overview. FDA has
verified the Web site addresses in this
document, as of the date this document
publishes in the Federal Register, but
Web sites are subject to change over
time.
Transcripts: Transcripts will not be
available.
Dated: March 16, 2017.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2017–05602 Filed 3–21–17; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of the Secretary
[Document Identifier: 0955–0009–60D]
Agency Information Collection
Activities; Proposed Collection; Public
Comment Request
AGENCY:
E:\FR\FM\22MRN1.SGM
Office of the Secretary, HHS.
22MRN1
Agencies
[Federal Register Volume 82, Number 54 (Wednesday, March 22, 2017)]
[Notices]
[Page 14734]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-05602]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2017-N-0001]
Food and Drug Administration Center for Drug Evaluation and
Research Small Business and Industry Assistance Regulatory Education
for Industry Generic Drugs Forum; Public Conference
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice of public conference.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) Center for Drug
Evaluation and Research (CDER) is sponsoring a 2-day public conference
entitled ``FDA CDER Small Business and Industry Assistance (SBIA)
Regulatory Education for Industry (REdI) Generic Drugs Forum.'' The
goal of this public conference is to provide direct, relevant, and
helpful information on the key aspects of the generic drug development
process. Our primary audience is that of small manufacturers within the
generic drug industry. However, anyone involved in the pharmaceutical
industry may attend.
DATES: The public conference will be held April 4-5, 2017, from 8:30
a.m. to 4:30 p.m. See the SUPPLEMENTARY INFORMATION section for
registration information.
ADDRESSES: The public conference will be held in the Pinnacle Ballroom
located on the 2nd floor of DoubleTree by Hilton Hotel, 8727 Colesville
Rd., Silver Spring, MD 20910.
FOR FURTHER INFORMATION CONTACT: Brenda Stodart, Center for Drug
Evaluation and Research, Food and Drug Administration, 10001 New
Hampshire Ave., Silver Spring, MD 20993-0002, 301-796-6707, email:
cdersbia@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
I. Background
FDA is announcing a public conference entitled ``FDA CDER Small
Business and Industry Assistance Regulatory Education for Industry
Generic Drugs Forum.'' This public conference is intended to increase
the generic drug industry's awareness of applicable FDA regulations.
II. Topics for Discussion at the Public Conference
This 2-day, FDA-led forum offers the opportunity to interact with
FDA subject matter experts from across CDER involved in the Generic
Drug Review Program. It will provide up-to-date information on program
progress and current initiatives and present a high-level regulatory
overview of the complete ANDA review pathway.
III. Participating in the Public Conference
Registration: There is no fee to attend the public conference.
Space is limited, and registration will be on a first-come, first-
served basis. To register, please complete registration online at:
https://www.fda.gov/Drugs/DevelopmentApprovalProcess/SmallBusinessAssistance/ucm540969.htm?utm_source=FRN&utm_campaign=GDF2017. Early registration
is recommended. Registrants will receive email confirmation when they
have been accepted, and reminder emails will be sent to registrants 2
days before the conference. If time and space permit, onsite
registration will be available beginning at 7:30 a.m. on each day of
the public conference.
If you need special accommodations due to disability, please
contact info@sbiaevents.com at least 7 days in advance.
Streaming Webcast of the Public Conference: This public conference
will also be webcast. Persons interested in viewing the webcast must
register to receive a confirmation email with the webcast link.
If you have never attended a Connect Pro event before, test your
connection at https://collaboration.fda.gov/common/help/en/support/meeting_test.htm. To get a quick overview of the Connect Pro program,
visit https://www.adobe.com/go/connectpro_overview. FDA has verified
the Web site addresses in this document, as of the date this document
publishes in the Federal Register, but Web sites are subject to change
over time.
Transcripts: Transcripts will not be available.
Dated: March 16, 2017.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2017-05602 Filed 3-21-17; 8:45 am]
BILLING CODE 4164-01-P